“The results of our retrospective study support taking advantage of the Cxbladder test to identify patients who should be further evaluated for cancer and to spare those who likely do not have cancer from an unnecessary workup," says Badrinath Konety, MD, MBA.
“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.
"A more standardized protocol that is office based, reliable, and reproducible as well as cost- and time-efficient is required to entice more urologists to abandon the TRUS-BX approach," writes J. Brantley Thrasher, MD.
Reduced infection rate may drive increased use of the transperineal approach.
Eating more vegetables will not alter the natural history of prostate cancer or otherwise prevent progression of localized disease, according to a recent study.
“To my knowledge, this is the first sanctioned guideline from a national organization that addresses the role of molecular biomarker testing for localized prostate cancer,” says guideline panel co-chair Scott E. Eggener, MD.
"Ignoring the entire Quality category may be a risky strategy in 2020 and beyond," warns Robert A. Dowling, MD.
"Category III codes are designated as temporary codes by the AMA. Even though the codes are considered temporary, they are an integral and important part of the system," write Jonathan Rubenstein, MD, and Mark Painter.
"Irrespective of treatment, fewer than half of men reported the ability to maintain erections sufficient for intercourse at 5 years," writes Badar M. Mian, MD.
A radiolabeled small molecule that binds to prostate-specific membrane antigen is continuing to show promise for treating progressive metastatic castrate-resistant prostate cancer, according to researchers at the University of California, Los Angeles.